Skip to main content

Rheumatoid Arthritis: Tuberculosis Screening (Recommended for eMeasure Trial Approval)

CBE ID
2522
Endorsed
Endorsement Status
Approved for Trial Use
1.1 New or Maintenance
Maintenance
E&M Cycle
Spring 2019
Is Under Review
No
Next Planned Maintenance Review
Fall 2025
1.3 Measure Description

Percentage of patients 18 years and older with a diagnosis of rheumatoid arthritis who have documentation of a tuberculosis (TB) screening performed within 6 months prior to receiving a first course of therapy using a biologic disease-modifying anti-rheumatic drug (DMARD).

    • 1.14 Numerator

      Any record of TB testing documented or performed (PPD, IFN-gamma release assays, or other appropriate method) in the medical record in the 12 months preceding the biologic DMARD prescription.

    • 1.15 Denominator

      Patients 18 years and older with a diagnosis of rheumatoid arthritis who are seen for at least one face-to-face encounter for RA who are newly started on biologic therapy during the measurement period.

    • Exclusions

      N/A

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Approved for Trial Use Primary Care and Chronic Illness Spring Cycle 2019
      Initial Endorsement
      Last Updated
    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off